Mgen (Mycoplasma genitalium) is already a highly prevalent sexually transmitted infection affecting 1% to 3% of the population in the USA, UK, Australia, and Scandinavia.
There have been many reports in the media describing how this pathogen may become the next superbug (BBC, CNN, The Daily Telegraph).
Mgen is often asymptomatic and there is not enough data to fully understand potential long-term health complications of this infection, so it is not recommended to test or screen for Mgen if you are not experiencing any symptoms.
In women, Mgen may cause inflammation of the cervix, pelvic inflammatory disease, and infertility.
In men, it may cause inflammation of the urethra, discharge from the penis and pain during urination.
Resistance Guided Therapy allows doctors to prescribe the best possible treatment for Mgen, improving treatment time and success for patients.
Patients with non-gonococcal urethritis are to be screened for Mgen and the pathogen’s resistant status to azithromycin.
Patients screened as positive for Mgen are given either a treatment plan including oral azithromycin or antibiotics known as ‘fluoroquinolones’ depending on the resistance status. This is outlined in the flowchart below.
Disclaimer: See a health professional if you are experiencing any symptoms. Diagnostic test results must be correlated with clinical history, epidemiological data, laboratory data and any other data available to the clinician.